Apo B and Lp(a): A clinician's perspective

Endocrinologist

Volumn 10, Issue 2, 2000, Pages 83-89

  Linde, Randy ^a,b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; RESIN; TRIACYLGLYCEROL;

ADULT; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; ELECTROPHORESIS; FAMILIAL DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; REVIEW;

EID: 0034116357     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200010020-00002     Document Type: Review

References (38)

1. Castelli WP, Anderson K: A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 1986; 8 (Suppl. 2A): 23-32.
2. Lovastatin Study Group II: Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. J Am Med Assoc 1986; 256: 2829-34.
3. de Lorgeril M, Salen P, Martin JL, et al.: Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. Arch Intern Med 1998; 158: 1181-7.
4. von Schacky C, Angerer P, Kothny W, et al.: The effect of dietary omega-3 fatty acids on coronary atherosclerosis. Ann Intern Med 1999; 130: 554-62.
5. Lichtenstein AH, Ausman LM, Jalbert SM, et al.: Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 1999; 340: 1933-40.
6. Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308-12.
7. Farnier M, Bonnefous F, Debbas N, et al.: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the Curves Study). Am J Cardiol 1998; 81: 582-7.
8. Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996; 1: 195-202.
9. Steinmetz A, Schwartz T, Hehnke U, et al.: Multicenter comparison of Micronized fenofibrate and simvastatin in patients with primary Type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996; 27: 563-70.
10. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
11. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group: Primary prevention of Acute Coronary Events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998; 279: 1615-22.
12. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(45). Lancet 1994; 344: 1383-9.
13. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigations: The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
14. Blankenhorn DH, Nession SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 1986; 256: 2829-34.
15. Herd JA, Ballantyne CM, Farmer JA, et al. for the LCAS Investigators: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86.
16. Grundy SM: Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436-9.
17. Davignon J, Genest J: Genetics of lipoprotein disorders. In Endocrinology and Metabolism Clinics of North America, edited by Hoeg JM, Philadelphia, WB Saunders 1998; 27: 521-50.
18. Goldstein JL, Schrott HG, Hazzard WR, et al.: Hyperlipidemia in coronary heart disease: II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-68.
19. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
20. Marcovina SM, Levine DM, Lippi G: Lipoprotein(a). Structure, measurement, and clinical significance. In Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins, edited by Rifai N, Warnick R, p. 235-63, Washington DC, AACC Press 1994.
21. Espeland MA, Marcovina SM, Miller V, et al.: Effect of post-menopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97: 979-86.
22. Rader DJ, Brewer HB: Lipoprotein(a): clinical approach to a unique atherogenic lipoprotein. J Am Med Assoc 1992; 267: 1109-12.
23. Seed M, Hoppichler F, Reaveley D, et al.: Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-9.
24. Mbwu AD, Bahatnagar PN, Durrington L, et al.: Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Aterioscler Thromb 1991; 11: 940-6.
25. Superko HR: Inclusion of lipoprotein subfractions among efficacy parameters. Am J Cardiol 1998; 81 (8A): 52f-55f.
26. Bjornheden TA, Babyi G, Bondjers G, et al.: Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996; 123: 43-56.
27. Austin MA, Hennekens CH, Breslow HL, et al.: Low density lipoprotein subclass patterns and risk of myocardial infarction: The Boston Area Health Study. Am J Epidemiol 1987; 126: 739-40.
28. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
29. National Cholesterol Education Program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 90: 1329-445.
30. Genest JJ, Martin-Munley SS, McNamara JR: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-33.
31. Utermann G: The mysteries of lipoprotein(a). Science 1989; 246: 904-10.
32. Scanu AM, Fless GM: Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-15.
33. Marcovina SM, Morrisett JD: Structure and metabolism of lipoprotein(a). Curr Opin Lipid 1995; 6: 135-45.
34. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-78.
35. Hirano K, Yamashita S, Kuga Y, et al.: Atherosclerosis disease in marked hyperalphalipoproteinemia. Combined reduction of cholesterol ester transfer protein and hepatic TG lipase. Arterioscler Thromb Vasc Biol 1995; 15: 1849-56.
36. 2 levels and decreased hepatic lipase activity. Metabolism 1998; 47: 965-73.
37. Maher VM, Brown BG, Marcovina SM, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 1995; 274: 1771-4.
38. Goldstein JL, Kita T, Brown MS: Defective lipoprotein receptors and athersclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 1983; 309: 288-96.